Skip to main content

Table 3 Treatment Related Toxicity

From: A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

  Grade 1/2 Grade 3/4
Toxicity No. % No. %
Hematologic     
Neutropenia 3 14 9 41
Anemia 8 36 1 5
Febrile neutropenia 0 0 2 9
Leukopenia 3 14 4 18
Lymphopenia 4 18 4 18
Non-hematologic     
Fatigue 21 95 1 5
Anorexia 17 77 7 32
Diarrhea 16 72 2 9
Mucositis 14 64 0 0
Rash 13 59 0 0
Liver enzyme elevation (AST) 12 55 0 0
Liver enzyme elevation (ALT) 9 41 0 0
Dizziness 9 41 0 0
Hypertension 7 32 0 0
Ocular irritation 7 32 0 0
\